Nano Pharmaceuticals
Market Cap
₹176 ₹176 Cr.
P/E
23.58
PEG = P/E ÷ 5yr forward EPS CAGR

The forward EPS CAGR is estimated individually for each company - factoring in its guidance, industry, and growth drivers - not generic rule-based projection.

Key Ratios

Debt to Equity
Debt to Equity
0.11
Div Yield (%)
Div Yield (%)
0.98
Individual < 2 lac
Individual < 2 lac
22.26 %
Institutions
Institutions
-
Market cap
Market cap
176 Cr
No. of Shareholders
No. of Shareholders
5,686
OPM (%)
OPM (%)
16.59 %
PE
PE
23.58
Prom Holding
Prom Holding
64.73 %
ROCE (%)
ROCE (%)
8.85
ROE (%)
ROE (%)
4.66
Sales
Sales
112 Cr
  • Smruthi Organics
  • Nectar Lifesciences
  • Bal Pharma
Last updated on 7 Oct 2026
  • Smruthi Organics makes bulk drugs and drug intermediates, including Metformin HCL and Diloxanide Furoate.
  • It sells to domestic buyers and export markets. Exports exceeded domestic sales in FY25.
  • It closed its finished-dosage formulations division, Smruthi Healthcare, in May 2026. Bulk drugs are now its only operating segment.
  • Base profit comes from bulk-drug sales. Management favours margins and long-term customers over low-priced domestic sales.
  • It holds European quality certification, EDQM, received in May 2026. An inspection by Brazil's health regulator, ANVISA, is still pending.
  • It is focusing on regulated exports and higher-margin contract research and manufacturing. Management expects only routine capital spending unless new capacity is needed.
  • First-quarter FY27 revenue recovered to ₹29.30Cr. Bulk-drug profit reached ₹3.89Cr after a year-ago loss. The comparison is distorted by costs moved into the segment.
  • Working capital remains strained, with ₹2.25Cr overdue over three years within ₹19.30Cr of receivables. Part of this is under court recovery.
  • It is in early rebound. Near-term earnings hinge on holding margins while rebuilding volumes.
  • It remains promoter-controlled. Managerial pay remains high and needs special shareholder approval.
  • First full bulk-drug-only quarter ~mid-Nov 2026
    it shows whether bulk-drug rebound holds and what formulation closure costs remain.
  • Brazil inspection and regulated order conversion next few quarters
    it decides whether European approval and Brazil clearance turn into higher-value contract manufacturing orders.
  • Old receivables recovery No timeline
    about ₹216L, about 11% of net receivables, is at stake and decides cash recovery versus write-off.
  • Labour court back-wage case No timeline
    ₹95.91L is at risk, about 28% of FY26 profit, and decides whether the payment becomes due.
Price Range

See where the stock is trading versus its 52-week high and low.

Low
95
52W Range
High
175
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

11 Yes

Positive for this company

1 Neutral

Neutral for this company

5 No

Negative for this company

0 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Operational Metrics

    Select a Metric
    • R&D as a % of Total Sales (%)

    Peer Comparison

    Corporate Actions

    Consolidated
    DATE
    DETAILS
    Show More
    Show Less
    Show More
    Show Less

    FAQs on Smruthi Organics Ltd. Business

    Smruthi Organics Ltd specializes in multi-step organic synthesis and large-scale manufacturing of various API and drug intermediates used in the pharmaceutical industry. Their product range includes a variety of essential medications and drug intermediates.

    Smruthi Organics major competitors are Bal Pharma, Nectar Lifesciences, Everest Organics, Tyche Industries, Mangalam Drugs&Org., Lasa Supergenerics, Haleos Labs.
    Market Cap of Smruthi Organics is ₹177 Crs.
    While the median market cap of its peers are ₹168 Crs.

    Smruthi Organics seems to be financially stable compared to its competitors.
    The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

    Company Filing

    2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
    Annual Report FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
    Earnings Release
    Investor Presentation
    Conference Call
    Conference Call SummaryCon Call Summary

    Discussions & Analysis

    Ideas Dashboard
    Results
    Timeline
    Watchlist
    Portfolio
    Alerts
    Stock Screener
    Market
    Raw Material